Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Alfosbuvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Alfosbuvir is an oral antiviral tablet for chronic hepatitis C, developed and made in China by Nanjing Sanhome Pharmaceutical, where it is sold as 圣诺迪® (Sanoldi®). It is always taken together with a second antiviral, daclatasvir. The two attack the hepatitis C virus at different points, and a 12-week course is aimed at clearing the virus from the body.
China's National Medical Products Administration (NMPA) approved it in May 2023, through its priority review route, for adults with:
It is a prescription liver medicine and should be used under a hepatologist or gastroenterologist.
The hepatitis C virus copies itself using an enzyme called NS5B polymerase. Alfosbuvir blocks that enzyme, while daclatasvir blocks a different viral protein, NS5A. Hitting the virus in two places at once makes it very hard for it to keep multiplying.
In the phase 3 study published in Infectious Diseases and Therapy in 2023, 326 adults in China took alfosbuvir with daclatasvir for 12 weeks. 98.2% were cured, meaning no virus could be found 12 weeks after the last tablet (SVR12). The cure rate was 99.3% in people without cirrhosis and 92.7% in those with compensated cirrhosis. It worked across genotypes 1, 2, 3 and 6, including 100% of the 95 patients with genotype 2a.
The dose should not be reduced, and it is never taken on its own. If daclatasvir is stopped, alfosbuvir is stopped too.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Never used alone: it only works as part of a two-drug combination. Read the prescribing information of daclatasvir as well, since its own warnings and drug interactions also apply.
Side effects in the trial: most were mild. 7.7% of patients had a serious health event during the study, but none was judged to be caused by the medicines. Only one patient (0.3%) stopped treatment, because of liver cancer, and no one died. Safety in pregnancy and breastfeeding has not been established in the published data, so discuss this with your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because it is always taken with daclatasvir, your doctor will plan both medicines together.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 42 tablets of 100 mg, which is one week of treatment at six tablets a day, so a full 12-week course needs 12 boxes. The tablets travel in their sealed original packs under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid specialist's prescription.
Liver clinics in Delhi see patients from all over North India. Being close to our New Delhi dispatch point means the tablets can reach the patient quickly.
Hepatologists in Mumbai can request the medicine for a named patient, with the full 12-week supply planned in one go so there is no gap in treatment.
Patients in Bangalore can have the tablets delivered home or to their liver clinic once the documents are checked.
A major centre for gastroenterology in South India, with experience in managing imported medicines for individual patients.
Liver specialists in Hyderabad can share the prescription and genotype report with us to start the import.
For Kolkata and the eastern states, we plan deliveries so the course can begin on the date the doctor has set.
Patients in Pune can use the same documented import route, with updates shared at every step.
Gastroenterologists in Ahmedabad can coordinate access for patients who need this specific combination.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
Patients in Rajasthan can receive the medicine without travelling, as long as the import is in their name.
We coordinate delivery for patients treated at public and private liver clinics across Uttar Pradesh.
Patients across Kerala can have the full course delivered to their home or clinic in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 16 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
